Showing results (511-520 of 658) with videos related to
Sort By:
Pageof 66
Neuro-Oncology Advances|May 11, 2022
Proceedings of the Survivorship Care in Neuro-Oncology Workshop sponsored by the Comprehensive Oncology Network Evaluating Rare CNS Tumors (NCI-CONNECT)Heather E Leeper, Emily Tonorezos, Deborah Mayer, et al.Cancers|December 10, 2021
Tumor Mutation Burden, Expressed Neoantigens and the Immune Microenvironment in Diffuse GliomasGuangyang Yu, Ying Pang, Mythili Merchant, et al.Neuro-Oncology Practice|December 14, 2019
The association between BMI and BSA-temozolomide-induced myelosuppression toxicities: a correlative analysis of NRG oncology RTOG 0525H Ian Robins, Jens Eickhoff, Mark R Gilbert, et al.The Lancet. Oncology|November 8, 2015
Immunotherapy response assessment in neuro-oncology: a report of the RANO working groupHideho Okada, Michael Weller, Raymond Huang, et al.Neuro-Oncology Advances|February 23, 2023
Discovery of clinical and demographic determinants of symptom burden in primary brain tumor patients using network analysis and unsupervised clusteringBrandon H Bergsneider, Elizabeth Vera, Ophir Gal, et al.Neuro-Oncology Practice|February 7, 2025
The COVID-19 pandemic experience for patients with central nervous system tumors: Differences in patient-reported outcomes and practice recommendationsAmanda L King, Kayla N Roche, Elizabeth Vera, et al.Nature Communications|January 28, 2021
IDH1 mutations induce organelle defects via dysregulated phospholipidsAdrian Lita, Artem Pliss, Andrey Kuzmin, et al.Neuro-Oncology Advances|October 2, 2020
Proceedings of the Comprehensive Oncology Network Evaluating Rare CNS Tumors (NCI-CONNECT) Adult Medulloblastoma WorkshopMarta Penas-Prado, Brett J Theeler, Brittany Cordeiro, et al.Cancer & Metabolism|October 26, 2020
Metabolic plasticity of IDH1-mutant glioma cell lines is responsible for low sensitivity to glutaminase inhibitionVictor Ruiz-Rodado, Adrian Lita, Tyrone Dowdy, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 6, 2010
Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastomaJohn H Sampson, Amy B Heimberger, Gary E Archer, et al.Pageof 66